Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: Systematic review

BMJ Oct 11, 2018

Matthews A, et al. - In women with a history of non-metastatic breast cancer, researchers examined the impact of endocrine therapies on a wide range of specific clinical cardiovascular disease outcomes. The totality of the randomized controlled trial and observational evidence suggested an increased risk of venous thromboembolism in tamoxifen users vs both non-users and aromatase inhibitor users. Data also indicated a higher risk of vascular diseases, myocardial infarction, and angina in...

Go to Original

Non loggedin lock

To read this article Sign up / Login for free

This article is only available to members. Are you a doctor? Click here to signup for free.